These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches. Volpe G; Cignetti A; Panuzzo C; Kuka M; Vitaggio K; Brancaccio M; Perrone G; Rinaldi M; Prato G; Fava M; Geuna M; Pautasso M; Casnici C; Signori E; Tonon G; Tarone G; Marelli O; Fazio VM; Saglio G Cancer Res; 2007 Jun; 67(11):5300-7. PubMed ID: 17545610 [TBL] [Abstract][Full Text] [Related]
5. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas. Soda G; Antonaci A; Bosco D; Nardoni S; Melis M J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183 [TBL] [Abstract][Full Text] [Related]
6. MHC-binding peptides as immunotherapeutics for cancer. Kobayashi H; Kennedy R; Lu J; Davila E; Celis E Immunol Invest; 2000 May; 29(2):105-10. PubMed ID: 10854176 [No Abstract] [Full Text] [Related]
7. Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells. Bacus SS; Yarden Y; Oren M; Chin DM; Lyass L; Zelnick CR; Kazarov A; Toyofuku W; Gray-Bablin J; Beerli RR; Hynes NE; Nikiforov M; Haffner R; Gudkov A; Keyomarsi K Oncogene; 1996 Jun; 12(12):2535-47. PubMed ID: 8700512 [TBL] [Abstract][Full Text] [Related]
8. T-cell immunity to oncogenic proteins including mutated ras and chimeric bcr-abl. Cheever MA; Chen W; Disis ML; Takahashi M; Peace DJ Ann N Y Acad Sci; 1993 Aug; 690():101-12. PubMed ID: 8103658 [TBL] [Abstract][Full Text] [Related]
9. Expression of molecular biomarkers in primary breast tumors implanted into a surrogate host: increased levels of cyclins correlate with tumor progression. Wani G; Noyes I; Milo GE; D'Ambrosio SM Mol Med; 1997 Apr; 3(4):273-83. PubMed ID: 9131589 [TBL] [Abstract][Full Text] [Related]
10. Oncogenic potential of c-erbB-2 and its association with c-K-ras in premalignant and malignant lesions of the human uterine endometrium. Manavi M; Bauer M; Baghestanian M; Berger A; Kucera E; Pischinger K; Battistutti W; Czerwenka K Tumour Biol; 2001; 22(5):299-309. PubMed ID: 11553860 [TBL] [Abstract][Full Text] [Related]
11. [Construction of genetically modified dendritic cell vaccine expressing bcr/abl fusion gene and inducing specific cytotoxic T lymphocytes to kill K562 cells in vitro]. Wang WW; Huang RW; Hu Y; Li XD; Wang DN; He Y; Liu JJ Ai Zheng; 2009 Jun; 28(6):602-6. PubMed ID: 19635197 [TBL] [Abstract][Full Text] [Related]
12. Significant difference in p53 and p21 protein immunoreactivity in HPV 16 positive and HPV negative breast carcinomas. Hennig EM; Kvinnsland S; Holm R; Nesland JM Acta Oncol; 1999; 38(7):931-8. PubMed ID: 10606422 [TBL] [Abstract][Full Text] [Related]
13. [Progress in molecular genetics of correlating genes of breast cancer]. Wu Y; Yang L; Wei Y Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Apr; 19(2):152-5. PubMed ID: 11941595 [TBL] [Abstract][Full Text] [Related]
14. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Bodey B; Bodey B; Siegel SE; Kaiser HE Anticancer Res; 2000; 20(4):2665-76. PubMed ID: 10953341 [TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of a p210(BCR-ABL) fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro. Sun JY; Krouse RS; Forman SJ; Senitzer D; Sniecinski I; Chatterjee S; Wong KK Cancer Res; 2002 Jun; 62(11):3175-83. PubMed ID: 12036931 [TBL] [Abstract][Full Text] [Related]
16. Analysis of the K-ras and p53 pathways in X-ray-induced lung tumors in the rat. Belinsky SA; Middleton SK; Picksley SM; Hahn FF; Nikula KJ Radiat Res; 1996 Apr; 145(4):449-56. PubMed ID: 8600505 [TBL] [Abstract][Full Text] [Related]
17. Immunity to oncogenic proteins. Cheever MA; Disis ML; Bernhard H; Gralow JR; Hand SL; Huseby ES; Qin HL; Takahashi M; Chen W Immunol Rev; 1995 Jun; 145():33-59. PubMed ID: 7590829 [No Abstract] [Full Text] [Related]
18. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454 [TBL] [Abstract][Full Text] [Related]
19. Time-dependent resveratrol-mediated mRNA and protein expression associated with cell cycle in WR-21 cells containing mutated human c-Ha-Ras. Young LF; Martin KR Mol Nutr Food Res; 2006 Jan; 50(1):70-7. PubMed ID: 16369916 [TBL] [Abstract][Full Text] [Related]
20. Cyclin-D1-gene amplification and expression in breast carcinoma: relation with clinicopathologic characteristics and with retinoblastoma gene product, p53 and p21WAF1 immunohistochemical expression. Barbareschi M; Pelosio P; Caffo O; Buttitta F; Pellegrini S; Barbazza R; Dalla Palma P; Bevilacqua G; Marchetti A Int J Cancer; 1997 Apr; 74(2):171-4. PubMed ID: 9133450 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]